Tempus AI

Tempus AI is a healthcare technology company that combines artificial intelligence, genomic testing, clinical data, and advanced analytics to support precision medicine. Founded in 2015, the Chicago-based company develops technologies that help physicians make more informed treatment decisions and help pharmaceutical and biotechnology companies accelerate drug discovery and clinical development. Its portfolio includes Tempus One, Tempus Next, Tempus Lens, genomic testing solutions, algorithmic models, and multimodal foundation models for healthcare and life sciences. Tempus operates one of the largest multimodal healthcare data platforms, bringing together clinical, molecular, imaging, and genomic information for research and patient-care applications.

 Its AI technologies can analyze large volumes of structured and unstructured medical information to identify patient cohorts, support clinical-trial matching, close care gaps, and generate evidence for drug development. In 2026, Tempus expanded its agentic AI capabilities through the next-generation Lens platform and upgraded Tempus Hub with an AI-enabled clinical co-pilot. The company also received FDA 510(k) clearance in August 2026 for Tempus ECG-PH, an AI-enabled device designed to detect signs associated with pulmonary hypertension from standard 12-lead ECGs.